Literature DB >> 7648994

The residual neuropsychological effects of cannabis: the current status of research.

H G Pope1, A J Gruber, D Yurgelun-Todd.   

Abstract

Evidence for the residual neuropsychological effects of cannabis must first be separated from evidence regarding (i) the acute effects of the drug, (ii) attributes of heavy cannabis users, and (iii) actual psychiatric disorders caused or exacerbated by cannabis. The remaining evidence must then be subdivided into (a) data supporting a 'drug residue' effect during the 12-24 h period immediately after acute intoxication and (b) data suggesting a more lasting toxic effect on the central nervous system which persists even after all drug residue has left the system. We reviewed the literature, comparing both 'drug-administration' studies in which known amounts of cannabis were administered to volunteers, and 'naturalistic studies' in which heavy marijuana users were tested after some period of abstinence. The data support a 'drug residue' effect on attention, psychomotor tasks, and short-term memory during the 12-24 h period immediately after cannabis use, but evidence is as yet insufficient to support or refute either a more prolonged 'drug residue' effect, or a toxic effect on the central nervous system that persists even after drug residues have left the body. We describe possible study designs to address these latter questions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648994     DOI: 10.1016/0376-8716(95)01097-i

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  41 in total

1.  The risks for late adolescence of early adolescent marijuana use.

Authors:  J S Brook; E B Balka; M Whiteman
Journal:  Am J Public Health       Date:  1999-10       Impact factor: 9.308

Review 2.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

Review 3.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

4.  Chronic cognitive impairment in users of 'ecstasy' and cannabis.

Authors:  Anthony Klugman; John Gruzelier
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

5.  Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.

Authors:  Alexander F Hoffman; Murat Oz; Ruiqin Yang; Aron H Lichtman; Carl R Lupica
Journal:  Learn Mem       Date:  2007-01-03       Impact factor: 2.460

6.  Long-term effects of frequent cannabis use on working memory and attention: an fMRI study.

Authors:  Gerry Jager; Rene S Kahn; Wim Van Den Brink; Jan M Van Ree; Nick F Ramsey
Journal:  Psychopharmacology (Berl)       Date:  2006-03-07       Impact factor: 4.530

Review 7.  Medical consequences of marijuana use: a review of current literature.

Authors:  Adam J Gordon; James W Conley; Joanne M Gordon
Journal:  Curr Psychiatry Rep       Date:  2013-12       Impact factor: 5.285

Review 8.  Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research.

Authors:  Lisa R Norman; Michael Basso; Anil Kumar; Robert Malow
Journal:  Curr Drug Abuse Rev       Date:  2009-05

9.  Alterations to pre-pulse inhibition (PPI) in chronic cannabis users are secondary to sustained attention deficits.

Authors:  Kirsty Elizabeth Scholes; Mathew Thomas Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

Review 10.  An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions.

Authors:  Rebecca D Crean; Natania A Crane; Barbara J Mason
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.